Prism MarketView

March 07, 2024 at 8:53 am

INmune Bio Demonstrates Significant Improvement in Alzheimer’s Disease Patients with Weekly XPro™ Treatment

Immunology company, INmune Bio, Inc. (Nasdaq: INMB) has demonstrated significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe… [Read More]

March 06, 2024 at 11:00 am

Lipella to Advance Oral Graft-versus-Host-Disease Candidate

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) has received FDA approval of an Investigational New Drug (IND) application for clinical testing of LP-410 in the treatment of… [Read More]

March 06, 2024 at 10:13 am

PRISM Psychedelics Index: atai Life Sciences Doses First Patient in Psychedelic Treatment Trial

Biopharmaceutical company, atai Life Sciences (Nasdaq: ATAI) joined the PRISM MarketView Emerging Psychedelics Index this week. The company was founded in response to the significant… [Read More]

March 06, 2024 at 9:24 am

IceCure’s ProSense® Delivers 100% Tumor Reduction in Early-Stage Breast Cancer

IceCure Medical Ltd. (Nasdaq: ICCM) has announced new data from a preliminary, independent breast cancer studyshowing median tumor reduction of 100% at six and 12… [Read More]

March 05, 2024 at 9:22 am

NRx Awaits Topline Data in Suicidal Bipolar Depression Treatment Trial

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has reached the ‘Last Patient, Last Visit’ milestone in its Phase 2b/3 Trial of NRX-101 in suicidal treatment resistant bipolar… [Read More]

March 05, 2024 at 8:42 am

Breakthrough Device Designation for Quanterix’s Alzheimer’s Diagnostic

High-definition diagnostics company, Quanterix Corporation (Nasdaq: QTRX), has been granted Breakthrough Device designation by the FDA for its Simoa® phospho-Tau 217 (p-Tau 217) blood test… [Read More]

March 04, 2024 at 3:54 pm

Quoin Pharmaceuticals to Include Teen Patients in Rare Disease Clinical Trials

Clinical stage biotechnology company, Quoin Pharmaceuticals (Nasdaq: QNRX) has received FDA clearance to recruit subjects aged 14 years and older into its two ongoing clinical… [Read More]

March 04, 2024 at 8:41 am

NeuroBo Pharmaceuticals to Initiate Clinical Trial in Obesity

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has received Institutional Review Board (IRB) approval to proceed with its Phase 1 clinical trial of DA-1726 for the treatment… [Read More]

March 01, 2024 at 12:57 pm

Lexaria to Advance CBD Hypertension Candidate with IND Approval

Lexaria Bioscience (Nasdaq: LEXX) continues to advance its CBD-based candidate for hypertension with the clearance of its investigational new drug (IND) application by the FDA… [Read More]

February 29, 2024 at 9:10 am

Adial Pharmaceuticals Lands Pivotal US Patent for Lead Product for Addiction Disorder Treatment; Shares Soar 229%

Adial Pharmaceuticals Inc (NASDAQ:ADIL) revealed that the United States Patent and Trademark Office issued patent number 11,905,562 on February 20, 2024. This new patent encompasses… [Read More]

February 29, 2024 at 9:06 am

Incannex’s Psilocybin Targets Anxiety with Positive Topline Results

Leading cannabinoid and psychedelic medicine biotechnology company, Incannex Healthcare (Nasdaq: IXHL), has achieved positive topline results in its Phase 2 clinical trial of psilocybin in… [Read More]

February 28, 2024 at 10:19 am

MindMed Closes Out 2023 with Positive Phase 2b Results for Generalized Anxiety Treatment

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD) has announced its financial results for the year ended December 31, 2023, closing out a “highly productive” year with… [Read More]

Tag: BIO TECH